Soltis Investment Advisors’s Revelation Biosciences Warrant REVBW Stock Holding History

Soltis Investment Advisors’s Portfolio REVBW Stock Details REVBW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$178	Sell	22,500 -25,000	-53%	-$260	﹤0.01%	648
2026 Q1	$318	Hold	47,500	–	–	﹤0.01%	580
2025 Q4	$380	Hold	47,500	–	–	﹤0.01%	528
2025 Q3	$499	Hold	47,500	–	–	﹤0.01%	478
2025 Q2	$570	Buy	+47,500	New	+$575	﹤0.01%	395

Other funds holding REVBW

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

PVI

Pine Valley Investments Marlton, New Jersey $2.53B AUM 36.18% 1-Year Est. Return

T3 Companies New York $93.7M AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Soltis Investment Advisors's REVBW Position: Q2 2026 in Review

Soltis Investment Advisors reduced its Revelation Biosciences Warrant (REVBW) stake by 53% in Q2 2026, selling an estimated $260 and leaving 22,500 shares worth $178. The position accounts for ﹤0.01% of the portfolio, ranked #648.

Soltis Investment Advisors first reported a position in REVBW in Q2 2025 and has held it in 5 quarters since. The position peaked at $570 in Q2 2025. 13 funds tracked by Wall St. Rank hold REVBW as of Q2 2026.

Soltis Investment Advisors held 22,500 shares of Revelation Biosciences Warrant worth $178 as of Q2 2026.
Soltis Investment Advisors sold 25,000 Revelation Biosciences Warrant shares in Q2 2026, an estimated $260.
Revelation Biosciences Warrant made up ﹤0.01% of Soltis Investment Advisors's portfolio in Q2 2026, its #648 holding.
Soltis Investment Advisors first reported a position in Revelation Biosciences Warrant in Q2 2025 and has held it in 5 quarters since.
Soltis Investment Advisors's Revelation Biosciences Warrant position peaked at $570 in Q2 2025.
13 funds tracked by Wall St. Rank held Revelation Biosciences Warrant as of Q2 2026.

Based on Soltis Investment Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.